Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor

Orit Wolstein, Maureen Boyd, Michelle Millington, Helen Impey, Joshua Boyer, Annett Howe, Frederic Delebecque, Kenneth Cornetta, Michael Rothe, Christopher Baum, Tamara Nicolson, Rachel Koldej, Jane Zhang, Naomi Keech, Joanna Camba Colón, Louis Breton, Jeffrey Bartlett, Dong Sung An, Irvin Sy Chen, Bryan Burke & 1 others Geoff P. Symonds

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Gene transfer has therapeutic potential for treating HIV-1 infection by generating cells that are resistant to the virus. We have engineered a novel self-inactivating lentiviral vector, LVsh5/C46, using two viral-entry inhibitors to block early steps of HIV-1 cycle. The LVsh5/C46 vector encodes a short hairpin RNA (shRNA) for downregulation of CCR5, in combination with the HIV-1 fusion inhibitor, C46. We demonstrate here the effective delivery of LVsh5/C46 to human T cell lines, peripheral blood mononuclear cells, primary CD4 + T lymphocytes, and CD34 + hematopoietic stem/progenitor cells (HSPC). CCR5-targeted shRNA (sh5) and C46 peptide were stably expressed in the target cells and were able to effectively protect gene-modified cells against infection with CCR5-and CXCR4-tropic strains of HIV-1. LVsh5/C46 treatment was nontoxic as assessed by cell growth and viability, was noninflammatory, and had no adverse effect on HSPC differentiation. LVsh5/C46 could be produced at a scale sufficient for clinical development and resulted in active viral particles with very low mutagenic potential and the absence of replication-competent lentivirus. Based on these in vitro results, plus additional in vivo safety and efficacy data, LVsh5/C46 is now being tested in a phase 1/2 clinical trial for the treatment of HIV-1 disease.

Original languageEnglish (US)
Article number11
JournalMolecular Therapy - Methods and Clinical Development
Volume1
DOIs
StatePublished - Jan 8 2014

Fingerprint

Small Interfering RNA
HIV-1
Hematopoietic Stem Cells
Safety
HIV Fusion Inhibitors
T-Lymphocytes
Lentivirus
Clinical Trials, Phase I
Virion
Genes
HIV Infections
Cell Differentiation
Blood Cells
Cell Survival
Down-Regulation
Viruses
Cell Line
Peptides
Growth
Infection

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine

Cite this

Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor. / Wolstein, Orit; Boyd, Maureen; Millington, Michelle; Impey, Helen; Boyer, Joshua; Howe, Annett; Delebecque, Frederic; Cornetta, Kenneth; Rothe, Michael; Baum, Christopher; Nicolson, Tamara; Koldej, Rachel; Zhang, Jane; Keech, Naomi; Camba Colón, Joanna; Breton, Louis; Bartlett, Jeffrey; An, Dong Sung; Chen, Irvin Sy; Burke, Bryan; Symonds, Geoff P.

In: Molecular Therapy - Methods and Clinical Development, Vol. 1, 11, 08.01.2014.

Research output: Contribution to journalArticle

Wolstein, O, Boyd, M, Millington, M, Impey, H, Boyer, J, Howe, A, Delebecque, F, Cornetta, K, Rothe, M, Baum, C, Nicolson, T, Koldej, R, Zhang, J, Keech, N, Camba Colón, J, Breton, L, Bartlett, J, An, DS, Chen, IS, Burke, B & Symonds, GP 2014, 'Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor', Molecular Therapy - Methods and Clinical Development, vol. 1, 11. https://doi.org/10.1038/mtm.2013.11
Wolstein, Orit ; Boyd, Maureen ; Millington, Michelle ; Impey, Helen ; Boyer, Joshua ; Howe, Annett ; Delebecque, Frederic ; Cornetta, Kenneth ; Rothe, Michael ; Baum, Christopher ; Nicolson, Tamara ; Koldej, Rachel ; Zhang, Jane ; Keech, Naomi ; Camba Colón, Joanna ; Breton, Louis ; Bartlett, Jeffrey ; An, Dong Sung ; Chen, Irvin Sy ; Burke, Bryan ; Symonds, Geoff P. / Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor. In: Molecular Therapy - Methods and Clinical Development. 2014 ; Vol. 1.
@article{085ca21fd0ce44e88766a7ada34aecf8,
title = "Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor",
abstract = "Gene transfer has therapeutic potential for treating HIV-1 infection by generating cells that are resistant to the virus. We have engineered a novel self-inactivating lentiviral vector, LVsh5/C46, using two viral-entry inhibitors to block early steps of HIV-1 cycle. The LVsh5/C46 vector encodes a short hairpin RNA (shRNA) for downregulation of CCR5, in combination with the HIV-1 fusion inhibitor, C46. We demonstrate here the effective delivery of LVsh5/C46 to human T cell lines, peripheral blood mononuclear cells, primary CD4 + T lymphocytes, and CD34 + hematopoietic stem/progenitor cells (HSPC). CCR5-targeted shRNA (sh5) and C46 peptide were stably expressed in the target cells and were able to effectively protect gene-modified cells against infection with CCR5-and CXCR4-tropic strains of HIV-1. LVsh5/C46 treatment was nontoxic as assessed by cell growth and viability, was noninflammatory, and had no adverse effect on HSPC differentiation. LVsh5/C46 could be produced at a scale sufficient for clinical development and resulted in active viral particles with very low mutagenic potential and the absence of replication-competent lentivirus. Based on these in vitro results, plus additional in vivo safety and efficacy data, LVsh5/C46 is now being tested in a phase 1/2 clinical trial for the treatment of HIV-1 disease.",
author = "Orit Wolstein and Maureen Boyd and Michelle Millington and Helen Impey and Joshua Boyer and Annett Howe and Frederic Delebecque and Kenneth Cornetta and Michael Rothe and Christopher Baum and Tamara Nicolson and Rachel Koldej and Jane Zhang and Naomi Keech and {Camba Col{\'o}n}, Joanna and Louis Breton and Jeffrey Bartlett and An, {Dong Sung} and Chen, {Irvin Sy} and Bryan Burke and Symonds, {Geoff P.}",
year = "2014",
month = "1",
day = "8",
doi = "10.1038/mtm.2013.11",
language = "English (US)",
volume = "1",
journal = "Molecular Therapy - Methods and Clinical Development",
issn = "2329-0501",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor

AU - Wolstein, Orit

AU - Boyd, Maureen

AU - Millington, Michelle

AU - Impey, Helen

AU - Boyer, Joshua

AU - Howe, Annett

AU - Delebecque, Frederic

AU - Cornetta, Kenneth

AU - Rothe, Michael

AU - Baum, Christopher

AU - Nicolson, Tamara

AU - Koldej, Rachel

AU - Zhang, Jane

AU - Keech, Naomi

AU - Camba Colón, Joanna

AU - Breton, Louis

AU - Bartlett, Jeffrey

AU - An, Dong Sung

AU - Chen, Irvin Sy

AU - Burke, Bryan

AU - Symonds, Geoff P.

PY - 2014/1/8

Y1 - 2014/1/8

N2 - Gene transfer has therapeutic potential for treating HIV-1 infection by generating cells that are resistant to the virus. We have engineered a novel self-inactivating lentiviral vector, LVsh5/C46, using two viral-entry inhibitors to block early steps of HIV-1 cycle. The LVsh5/C46 vector encodes a short hairpin RNA (shRNA) for downregulation of CCR5, in combination with the HIV-1 fusion inhibitor, C46. We demonstrate here the effective delivery of LVsh5/C46 to human T cell lines, peripheral blood mononuclear cells, primary CD4 + T lymphocytes, and CD34 + hematopoietic stem/progenitor cells (HSPC). CCR5-targeted shRNA (sh5) and C46 peptide were stably expressed in the target cells and were able to effectively protect gene-modified cells against infection with CCR5-and CXCR4-tropic strains of HIV-1. LVsh5/C46 treatment was nontoxic as assessed by cell growth and viability, was noninflammatory, and had no adverse effect on HSPC differentiation. LVsh5/C46 could be produced at a scale sufficient for clinical development and resulted in active viral particles with very low mutagenic potential and the absence of replication-competent lentivirus. Based on these in vitro results, plus additional in vivo safety and efficacy data, LVsh5/C46 is now being tested in a phase 1/2 clinical trial for the treatment of HIV-1 disease.

AB - Gene transfer has therapeutic potential for treating HIV-1 infection by generating cells that are resistant to the virus. We have engineered a novel self-inactivating lentiviral vector, LVsh5/C46, using two viral-entry inhibitors to block early steps of HIV-1 cycle. The LVsh5/C46 vector encodes a short hairpin RNA (shRNA) for downregulation of CCR5, in combination with the HIV-1 fusion inhibitor, C46. We demonstrate here the effective delivery of LVsh5/C46 to human T cell lines, peripheral blood mononuclear cells, primary CD4 + T lymphocytes, and CD34 + hematopoietic stem/progenitor cells (HSPC). CCR5-targeted shRNA (sh5) and C46 peptide were stably expressed in the target cells and were able to effectively protect gene-modified cells against infection with CCR5-and CXCR4-tropic strains of HIV-1. LVsh5/C46 treatment was nontoxic as assessed by cell growth and viability, was noninflammatory, and had no adverse effect on HSPC differentiation. LVsh5/C46 could be produced at a scale sufficient for clinical development and resulted in active viral particles with very low mutagenic potential and the absence of replication-competent lentivirus. Based on these in vitro results, plus additional in vivo safety and efficacy data, LVsh5/C46 is now being tested in a phase 1/2 clinical trial for the treatment of HIV-1 disease.

UR - http://www.scopus.com/inward/record.url?scp=84938412743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938412743&partnerID=8YFLogxK

U2 - 10.1038/mtm.2013.11

DO - 10.1038/mtm.2013.11

M3 - Article

VL - 1

JO - Molecular Therapy - Methods and Clinical Development

JF - Molecular Therapy - Methods and Clinical Development

SN - 2329-0501

M1 - 11

ER -